Please login to the form below
allergy
This page shows the latest allergy news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and Avillion’s asthma rescue treatment granted FDA approval
Current albuterol rescue inhalers alleviate acute symptoms, but do not treat the underlying inflammation in asthma,” explained Bradley Chipps, past president of the American College of Allergy, Asthma and Immunology and ... medical director of Capital
Latest news
-
AZ and Avillion’s asthma rescue treatment recommended by FDA Advisory Committee
PT027 significantly reduced the risk of severe asthma exacerbations. AstraZeneca (AZ) and Avillion’s PT027 (albuterol/budesonide) has been recommended by the US Food and Drug Administration’s (FDA) Pulmonary-Allergy ... exacerbations, regardless of
-
Gilead’s Veklury WHO recommendation expanded for treatment of severe COVID-19
Also supporting the recommendation were results from the National Institute of Allergy and Infectious Diseases' double-blind placebo-controlled ACTT-1 trial, which demonstrated a mortality reduction in Veklury-treated patients
-
Fauci addresses need for pan-coronavirus and intranasal vaccines to combat COVID-19 variants
The National Institute of Allergy and Infectious Diseases (NIAID) director specifically detailed the call for pan-coronavirus candidates and mucosal options that can be given to patients intranasally, all the while
-
FDA issues innovative proposal to increase nonprescription drug access
Nonprescription drugs provide an efficient, low-cost way to manage everyday health needs and include drugs for allergies, pain, fever and many more indications.
-
Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients
Bradley Chipps, past president of the American College of Allergy, Asthma &Immunology and medical director of the Capital Allergy &Respiratory Disease Center in the US, said: “This data further strengthens the
More from news
Approximately 17 fully matching, plus 244 partially matching documents found.
Latest Intelligence
-
Envisioning a healthier every day, for every woman
As a company working towards this promise, we are active in a range of therapy areas including reproductive health, heart disease, dermatology, allergies and asthma.
-
The pandemic preparedness paradox
In the United States, the National Institute of Allergy and Infectious Diseases alone spends $6bn annually in the labs of some of the best and brightest scientists in the world.
-
The search for effective drug treatments for COVID-19
medicine. to contribute to the medical response in public health emergencies. The EUA was based on then available data from two global clinical trials – the National Institute for Allergy and Infectious
-
Exploring the potential of eosinophils
when starting his research career in Southampton, UK before going on to be Professor of Allergy and Respiratory Medicine at Southampton University. ... Working as a clinician at this time meant he was caring for patients with allergies and asthma, in
-
As COVID-19 takes over the world, biopharma fights back
I don’t think the ongoing trials will tell us a lot,” said H Clifford Lane, clinical director at the National Institutes of Allergy and Infectious Diseases (NIAID).
More from intelligence
Approximately 1 fully matching, plus 26 partially matching documents found.
Latest appointments
-
New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare
Before AstraZeneca, she worked for GlaxoSmithKline for four years in a number of roles, including therapy specialist for its allergy portfolio.
-
ALK-Abello appoints Søren Jelert as CFO
He will be based at the company’s headquarters in Denmark. Dansih allergy immunotherapy company ALK-Abello has appointed Søren Jelert as its new chief financial officer, a role that sees ... to become a truly global allergy company.”.
-
Cytovation expands management team
Grego is currently chief executive officer of Spire Bioventures, a global healthcare consultancy and mentoring service, and has previously held a number of management positions at Spanish allergy specialist Laboratorios LETI.
-
Lars Dreiøe joins Sobi in senior quality and compliance role
He will join the firm in January from Danish allergy vaccine company ALK Abelló, where he was international head of quality.
-
ARC names chairman and member of the board
ARC is a privately held biopharma company developing desensitisation treatments for food allergies. ... Iwicki said: “ARC is working to address a very compelling therapeutic area and provide an option to those dealing with food allergies.
More from appointments
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest from PMHub
-
Pharmacogenomics supports and new era of precision medicine
even what allergies might come into play throughout the treatment journey.
-
Medscape Education Global
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide.
-
Food Allergy – Is avoidance the only option?
Allergy or intolerance. An important distinction to make when discussing food allergies is the difference between an allergy and an intolerance:. ... 2. Living with a food allergy. While food allergies can emerge at any age, the majority tend to develop
-
5 ways that lockdowns and restrictions could be affecting our allergies
Allergies are common, with around 44% of UK adults suffering from at least one allergy. ... For Allergy Awareness week 2021, we explored some of the significant ways that this may have impacted our experiences with allergies.
-
Lifesaving QR Code Wearable Launched to Help Emergency Services
Whilst a mi-SOS user can inform the public about underlying health conditions, a user can also update their profile with additional details such as allergies, critical care plans, COVID-19
More from PMHub
Approximately 5 fully matching, plus 15 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
PMHub
Medscape Medical Affairs
Medscape Medical Affairs enables all medical affairs professionals to take a more strategic leadership role, and maximize the impact of...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
